The role and impact of macrophages in the pathogenesis of primary biliary cholangitis

Di MA; Wenlin TAI

doi:10.12449/JCH240126

Volume 40 Issue 1

Jan. 2024

Turn off MathJax

Article Contents

Article Navigation > Journal of Clinical Hepatology > 2024 > 40(1): 157-160

PDF( 542 KB)

The role and impact of macrophages in the pathogenesis of primary biliary cholangitis

DOI: 10.12449/JCH240126

Di MA,
Wenlin TAI^{,
,}

Department of Clinical Laboratory，The Second Affiliated Hospital of Kunming Medical University，Kunming 650101，China

Research funding:

National Natural Science Foundation of China (82060385);

The Postgraduate Innovation Fund Project of Kunming Medical University 2023 (2023S321)

More Information

Corresponding author: TAI Wenlin， taiwenlin2685@163.com （ORCID： 0000-0002-8278-929X）
Received Date: 2023-03-25
Accepted Date: 2023-04-15
Published Date: 2024-01-23

Abstract

Abstract

Primary biliary cholangitis （PBC） is a chronic autoimmune disease of cholestasis in which immune factors lead to progressive small bile duct destruction， cholestasis， and eventually liver fibrosis， liver cirrhosis， and even liver failure. Macrophages， as a group with functional heterogeneity， play different roles in the whole disease process of PBC. This article summarizes the possible ways by which macrophages are involved in the pathogenesis of PBC and discusses their impact on the disease and the potential therapeutic targets of macrophages. It is pointed out that macrophages are mainly involved in innate immunity in PBC injury and are associated with gut microbiota dysbiosis， and they are also associated with cholestasis， liver fibrosis， and liver cirrhosis in the later stages of the disease.
- Primary Biliary Cholangitis,
- Macrophages,
- Pathologic Processes

FullText(HTML)

References(33)

References

[1]	GULAMHUSEIN AF, HIRSCHFIELD GM. Primary biliary cholangitis: Pathogenesis and therapeutic opportunities[J]. Nat Rev Gastroenterol Hepatol, 2020, 17( 2): 93- 110. DOI: 10.1038/s41575-019-0226-7.
[2]	LLEO A, WANG GQ, GERSHWIN ME, et al. Primary biliary cholangitis[J]. Lancet, 2020, 396( 10266): 1915- 1926. DOI: 10.1016/S0140-6736(20)31607-X.
[3]	COLAPIETRO F, BERTAZZONI A, LLEO A. Contemporary epidemiology of primary biliary cholangitis[J]. Clin Liver Dis, 2022, 26( 4): 555- 570. DOI: 10.1016/j.cld.2022.06.001.
[4]	LI H, GUAN YL, HAN CC, et al. The pathogenesis, models and therapeutic advances of primary biliary cholangitis[J]. Biomed Pharmacother, 2021, 140: 111754. DOI: 10.1016/j.biopha.2021.111754.
[5]	WU Y, FAN XX, YU HC, et al. Macrophage polarization is involved in liver fibrosis induced by β₁-adrenoceptor autoantibody[J]. Acta Biochim Biophys Sin, 2022, 54( 8): 1100- 1112. DOI: 10.3724/abbs.2022102.
[6]	HEYMANN F, TACKE F. Immunology in the liver: From homeostasis to disease[J]. Nat Rev Gastroenterol Hepatol, 2016, 13( 2): 88- 110. DOI: 10.1038/nrgastro.2015.200.
[7]	RONCA V, MANCUSO C, MILANI C, et al. Immune system and cholangiocytes: A puzzling affair in primary biliary cholangitis[J]. J Leukoc Biol, 2020, 108( 2): 659- 671. DOI: 10.1002/JLB.5MR0320-200R.
[8]	LLEO A, LEUNG PSC, HIRSCHFIELD GM, et al. The pathogenesis of primary biliary cholangitis: A comprehensive review[J]. Semin Liver Dis, 2020, 40( 1): 34- 48. DOI: 10.1055/s-0039-1697617.
[9]	MA WT, CHEN DK. Immunological abnormalities in patients with primary biliary cholangitis[J]. Clin Sci, 2019, 133( 6): 741- 760. DOI: 10.1042/CS20181123.
[10]	SHAO T, LEUNG PSC, ZHANG W, et al. Treatment with a JAK1/2 inhibitor ameliorates murine autoimmune cholangitis induced by IFN overexpression[J]. Cell Mol Immunol, 2022, 19( 10): 1130- 1140. DOI: 10.1038/s41423-022-00904-y.
[11]	TIAN XB, WANG Y, LU Y, et al. Conditional depletion of macrophages ameliorates cholestatic liver injury and fibrosis via lncRNA-H19[J]. Cell Death Dis, 2021, 12( 7): 646. DOI: 10.1038/s41419-021-03931-1.
[12]	ZHANG XM, THOMPKINS-JOHNS A, ZIOBER A, et al. Hepatic macrophage types cluster with disease etiology in chronic liver disease and differ compared to normal liver: Implications for their biologic and diagnostic role[J]. Int J Surg Pathol, 2023, 31( 3): 268- 279. DOI: 10.1177/10668969221099630.
[13]	BRUNEAU A, GUILLOT A, TACKE F. Macrophages in cholangiopathies[J]. Curr Opin Gastroenterol, 2022, 38( 2): 114- 120. DOI: 10.1097/MOG.0000000000000814.
[14]	FU HY, BAO WM, YANG CX, et al. Kupffer cells regulate natural killer cells via the NK group 2, member D(NKG2D)/retinoic acid early inducible-1(RAE-1) interaction and cytokines in a primary biliary cholangitis mouse model[J]. Med Sci Monit, 2020, 26: e923726. DOI: 10.12659/MSM.923726.
[15]	LI X, LIU RP, WANG YY, et al. Cholangiocyte-derived exosomal lncRNA H19 promotes macrophage activation and hepatic inflammation under cholestatic conditions[J]. Cells, 2020, 9( 1): 190. DOI: 10.3390/cells9010190.
[16]	YANG Y, CHOI J, CHEN Y, et al. E. coli and the etiology of human PBC: Antimitochondrial antibodies and spreading determinants[J]. Hepatology, 2022, 75( 2): 266- 279. DOI: 10.1002/hep.32172.
[17]	REUVENI D, GORE Y, LEUNG PSC, et al. The critical role of chemokine(C-C motif) receptor 2-positive monocytes in autoimmune cholangitis[J]. Front Immunol, 2018, 9: 1852. DOI: 10.3389/fimmu.2018.01852.
[18]	CHEN RL, TANG RQ, MA X, et al. Immunologic responses and the pathophysiology of primary biliary cholangitis[J]. Clin Liver Dis, 2022, 26( 4): 583- 611. DOI: 10.1016/j.cld.2022.06.003.
[19]	DUKIĆ M, RADONJIĆ T, JOVANOVIĆ I, et al. Alcohol, inflammation, and microbiota in alcoholic liver disease[J]. Int J Mol Sci, 2023, 24( 4): 3735. DOI: 10.3390/ijms24043735.
[20]	CADAMURO M, GIRARDI N, GORES GJ, et al. The emerging role of macrophages in chronic cholangiopathies featuring biliary fibrosis: An attractive therapeutic target for orphan diseases[J]. Front Med, 2020, 7: 115. DOI: 10.3389/fmed.2020.00115.
[21]	PINTO C, GIORDANO DM, MARONI L, et al. Role of inflammation and proinflammatory cytokines in cholangiocyte pathophysiology[J]. Biochim Biophys Acta Mol Basis Dis, 2018, 1864( 4 Pt B): 1270- 1278. DOI: 10.1016/j.bbadis.2017.07.024.
[22]	TANAKA A. Current understanding of primary biliary cholangitis[J]. Clin Mol Hepatol, 2021, 27( 1): 1- 21. DOI: 10.3350/cmh.2020.0028.
[23]	RONCA V, CHEN QB, LYGOURA V, et al. Autoantibodies in patients with interleukin 12 receptor beta 1 deficiency[J]. J Dig Dis, 2019, 20( 7): 363- 370. DOI: 10.1111/1751-2980.12790.
[24]	MAYO MJ. Mechanisms and molecules: What are the treatment targets for primary biliary cholangitis?[J]. Hepatology, 2022, 76( 2): 518- 531. DOI: 10.1002/hep.32405.
[25]	MU N, LIN F, JIANG ZG, et al. Characteristics of serum chemokine profile in primary biliary cholangitis[J]. Cytokine, 2020, 136: 155291. DOI: 10.1016/j.cyto.2020.155291.
[26]	RAMACHANDRAN P, DOBIE R, WILSON-KANAMORI JR, et al. Resolving the fibrotic niche of human liver cirrhosis at single-cell level[J]. Nature, 2019, 575( 7783): 512- 518. DOI: 10.1038/s41586-019-1631-3.
[27]	BUONOMO EL, MEI SL, GUINN SR, et al. Liver stromal cells restrict macrophage maturation and stromal IL-6 limits the differentiation of cirrhosis-linked macrophages[J]. J Hepatol, 2022, 76( 5): 1127- 1137. DOI: 10.1016/j.jhep.2021.12.036.
[28]	DAEMEN S, GAINULLINA A, KALUGOTLA G, et al. Dynamic shifts in the composition of resident and recruited macrophages influence tissue remodeling in NASH[J]. Cell Rep, 2021, 34( 2): 108626. DOI: 10.1016/j.celrep.2020.108626.
[29]	GUILLOT A, WINKLER M, SILVA AFONSO M, et al. Mapping the hepatic immune landscape identifies monocytic macrophages as key drivers of steatohepatitis and cholangiopathy progression[J]. Hepatology, 2023, 78( 1): 150- 166. DOI: 10.1097/HEP.0000000000000270.
[30]	CAI SY, GE MX, MENNONE A, et al. Inflammasome is activated in the liver of cholestatic patients and aggravates hepatic injury in bile duct-ligated mouse[J]. Cell Mol Gastroenterol Hepatol, 2020, 9( 4): 679- 688. DOI: 10.1016/j.jcmgh.2019.12.008.
[31]	LIAO M, LIAO JW, QU JQ, et al. Hepatic TNFRSF12A promotes bile acid-induced hepatocyte pyroptosis through NFκB/Caspase-1/GSDMD signaling in cholestasis[J]. Cell Death Discov, 2023, 9( 1): 26. DOI: 10.1038/s41420-023-01326-z.
[32]	KODA S, ZHANG BB, ZHOU QY, et al. β2-adrenergic receptor enhances the alternatively activated macrophages and promotes biliary injuries caused by helminth infection[J]. Front Immunol, 2021, 12: 754208. DOI: 10.3389/fimmu.2021.754208.
[33]	GALLUCCI GM, ALSUWAYT B, AUCLAIR AM, et al. Fenofibrate downregulates NF-κB signaling to inhibit pro-inflammatory cytokine secretion in human THP-1 macrophages and during primary biliary cholangitis[J]. Inflammation, 2022, 45( 6): 2570- 2581. DOI: 10.1007/s10753-022-01713-1.

Relative Articles

Supplements(0)

Cited By

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Get Citation

PDF

XML

Article Metrics

Article views (260) PDF downloads(40)

The role and impact of macrophages in the pathogenesis of primary biliary cholangitis

DOI: 10.12449/JCH240126

Abstract

References

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

The role and impact of macrophages in the pathogenesis of primary biliary cholangitis

DOI: 10.12449/JCH240126

Abstract

References

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

About Journal

Submission Guideline

Journal Online

Hepatobiliary College

Guidelines

Export File

Citation

Format

Content